Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CHA i-Cord is the cord blood banking division of CHA Biotech, a leading South Korean biotechnology company focused on regenerative medicine. The company provides comprehensive services for the collection, processing, and long-term cryopreservation of umbilical cord blood and cord tissue stem cells. Leveraging the extensive clinical and research network of the CHA Medical Group, i-Cord supports both private family banking and public donation programs. Its stored stem cells are utilized for treating a wide range of hematological and immunological disorders, and the company is actively involved in clinical research for novel applications in neurology and metabolic diseases. i-Cord is integrated into a broader ecosystem that includes cell therapy manufacturing and specialized medical centers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on i-Cord Cord Blood Bank.